FDA Issues Warning Letter to Amphastar Subsidiary Over Manufacturing Violations

summarizeSummary

Amphastar Pharmaceuticals' subsidiary received an FDA Warning Letter citing significant manufacturing practice violations, indicating heightened regulatory risk despite no immediate product restrictions.

check_boxKey Events · Legal and Risk Events · AMPH

• FDA Warning Letter Received

  International Medication Systems (IMS), a subsidiary, received a Warning Letter from the FDA on July 2, 2026, citing Current Good Manufacturing Practice (CGMP) violations at its South El Monte facility.

• CGMP Violations Identified

  The violations relate to investigation procedures, environmental monitoring, handling procedures, and manufacturing equipment, following a December 2025 inspection.

• No Immediate Product Restrictions

  The Warning Letter does not currently require IMS to cease or restrict product manufacturing or issue a further recall, and the facility continues to operate.

• Remediation Plan Required

  IMS must submit an initial response within 15 working days, conduct a risk assessment, and provide a remediation plan to address the deficiencies.

auto_awesomeAnalysis · AMPH · Life Sciences

Amphastar's subsidiary, International Medication Systems (IMS), received a formal FDA Warning Letter for Current Good Manufacturing Practice (CGMP) violations at its South El Monte facility. This escalates the regulatory scrutiny following an 'Official Action Indicated' classification disclosed in the Q1 2026 10-Q. While the letter does not immediately halt production or require a recall, it signals serious deficiencies that must be addressed. Failure to resolve these issues to the FDA's satisfaction could lead to more severe regulatory actions, impacting product supply and financial performance. The company's inability to assure FDA satisfaction or timing of resolution adds uncertainty.